| Year |
Citation |
Score |
| 2023 |
Dutta AK, Armstrong C, Luo D, Das B, Spencer B, Rissman RA. Reverses Motor Deficits and Reduces Accumulation of Human α-Synuclein Protein in Two Different Parkinson's Disease Animal Models. Acs Chemical Neuroscience. PMID 36749600 DOI: 10.1021/acschemneuro.2c00655 |
0.309 |
|
| 2022 |
Dinda B, Das B, Biswas S, Sharma H, Armstrong C, Yedlapudi D, Antonio T, Reith M, Dutta AK. Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein. Bioorganic & Medicinal Chemistry. 78: 117131. PMID 36571976 DOI: 10.1016/j.bmc.2022.117131 |
0.71 |
|
| 2020 |
Ziu I, Rettig I, Luo D, Dutta A, McCormick TM, Wu C, Martic S. The multifunctional dopamine D/D receptor agonists also possess inhibitory activity against the full-length tau441 protein aggregation. Bioorganic & Medicinal Chemistry. 28: 115667. PMID 32828429 DOI: 10.1016/J.Bmc.2020.115667 |
0.387 |
|
| 2019 |
Yedlapudi D, Xu L, Luo D, Marsh GB, Todi SV, Dutta AK. Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson's disease with dementia. Scientific Reports. 9: 19648. PMID 31873106 DOI: 10.1038/s41598-019-55830-3 |
0.45 |
|
| 2019 |
Dutta AK, Santra S, Harutyunyan A, Das B, Michael Lisieski, Xu L, Antonio T, Reith MEA, Perrine SA. D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD effects in rats. European Journal of Pharmacology. 172632. PMID 31473161 DOI: 10.1016/J.Ejphar.2019.172632 |
0.324 |
|
| 2019 |
Lisieski M, Harutyunyan A, Das B, Liberzon I, Bymaster F, Hsu T, Reith M, Perrine S, Dutta A. F9. A Novel Orally Active Triple Reuptake Inhibitor for the Treatment of Post-Traumatic Stress Disorder (PTSD): D-578 Attenuates Abnormal Fear Behavior in a Rodent Model of Traumatic Stress Biological Psychiatry. 85: S216. DOI: 10.1016/J.Biopsych.2019.03.546 |
0.314 |
|
| 2018 |
Elmabruk A, Das B, Yedlapudi D, Xu L, Antonio T, Reith MEA, Dutta AK. Design, Synthesis and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease. Acs Chemical Neuroscience. PMID 30301349 DOI: 10.1021/Acschemneuro.8B00291 |
0.557 |
|
| 2017 |
Lindenbach D, Das B, Conti MM, Meadows SM, Dutta AK, Bishop C. D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats. British Journal of Pharmacology. PMID 28667675 DOI: 10.1111/Bph.13937 |
0.531 |
|
| 2017 |
Singh SK, Dutta A, Modi G. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease. Future Medicinal Chemistry. PMID 28632413 DOI: 10.4155/Fmc-2017-0016 |
0.712 |
|
| 2017 |
Das B, Rajagopalan S, Joshi GS, Xu L, Luo D, Andersen JK, Todi SV, Dutta AK. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo. Neuropharmacology. PMID 28533164 DOI: 10.1016/J.Neuropharm.2017.05.019 |
0.496 |
|
| 2017 |
Das B, Kandegedara A, Xu L, Antonio T, Stemmler T, Reith MEA, Dutta AK. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease. Acs Chemical Neuroscience. 8: 723-730. PMID 28106982 DOI: 10.1021/Acschemneuro.6B00356 |
0.395 |
|
| 2016 |
Yedlapudi D, Joshi GS, Luo D, Todi SV, Dutta AK. Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Scientific Reports. 6: 38510. PMID 27917933 DOI: 10.1038/srep38510 |
0.339 |
|
| 2016 |
Luo D, Sharma H, Yedlapudi D, Antonio T, Reith MEA, Dutta AK. Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties. Bioorganic & Medicinal Chemistry. 24: 5088-5102. PMID 27591013 DOI: 10.1016/J.Bmc.2016.08.021 |
0.422 |
|
| 2016 |
Dholkawala F, Voshavar C, Dutta AK. Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 103: 62-70. PMID 26994936 DOI: 10.1016/j.ejpb.2016.03.017 |
0.472 |
|
| 2016 |
Zhen J, Antonio T, Jacob JC, Grandy DK, Reith MEA, Dutta AK, Selley DE. Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors. Neurochemical Research. 41: 328-339. PMID 26718829 DOI: 10.1007/S11064-015-1808-6 |
0.476 |
|
| 2015 |
Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? Future Medicinal Chemistry. PMID 26619226 DOI: 10.4155/Fmc.15.134 |
0.302 |
|
| 2015 |
Das B, Vedachalam S, Luo D, Antonio T, Reith ME, Dutta AK. Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease. Journal of Medicinal Chemistry. 58: 9179-95. PMID 26555041 DOI: 10.1021/Acs.Jmedchem.5B01031 |
0.516 |
|
| 2015 |
Voshavar C, Shah M, Xu L, Dutta AK. Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease. Neurotoxicity Research. 28: 302-18. PMID 26201265 DOI: 10.1007/S12640-015-9548-6 |
0.803 |
|
| 2015 |
Biswas S, Dutta A, Dolai M, Bhowmick I, Rouzières M, Clérac R, Panja A, Ali M. Novel Cu(II)-M(II)-Cu(II) (M = Cu or Ni) trinuclear and [NaCu] hexanuclear complexes assembled by bi-compartmental ligands: syntheses, structures, magnetic and catalytic studies. Dalton Transactions (Cambridge, England : 2003). 44: 9426-38. PMID 25915730 DOI: 10.1039/C4Dt03728F |
0.44 |
|
| 2015 |
Zhen J, Antonio T, Ali S, Neve KA, Dutta AK, Reith ME. Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTPγS assays. Journal of Neuroscience Methods. 248: 7-15. PMID 25840364 DOI: 10.1016/J.Jneumeth.2015.03.028 |
0.413 |
|
| 2015 |
Das B, Modi G, Dutta A. Dopamine D3 agonists in the treatment of Parkinson's disease. Current Topics in Medicinal Chemistry. 15: 908-26. PMID 25832718 DOI: 10.2174/156802661510150328223428 |
0.779 |
|
| 2015 |
Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template. Bioorganic & Medicinal Chemistry. 23: 821-8. PMID 25593099 DOI: 10.1016/J.Bmc.2014.12.040 |
0.36 |
|
| 2015 |
Voshavar C, Shah M, Xu L, Dutta AK. Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson’s Disease Neurotoxicity Research. DOI: 10.1007/s12640-015-9548-6 |
0.365 |
|
| 2014 |
Dutta AK, Santra S, Sharma H, Voshavar C, Xu L, Mabrouk O, Antonio T, Reith ME. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters. Plos One. 9: e113420. PMID 25427177 DOI: 10.1371/Journal.Pone.0113420 |
0.367 |
|
| 2014 |
Modi G, Sharma H, Kharkar PS, Dutta AK. Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation. Medchemcomm. 5: 1384-1399. PMID 25221669 DOI: 10.1039/C4Md00159A |
0.784 |
|
| 2014 |
Modi G, Voshavar C, Gogoi S, Shah M, Antonio T, Reith ME, Dutta AK. Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates. Acs Chemical Neuroscience. 5: 700-17. PMID 24960209 DOI: 10.1021/Cn500084X |
0.793 |
|
| 2014 |
Shah M, Rajagopalan S, Xu L, Voshavar C, Shurubor Y, Beal F, Andersen JK, Dutta AK. The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Journal of Neurochemistry. 131: 74-85. PMID 24848702 DOI: 10.1111/Jnc.12767 |
0.82 |
|
| 2014 |
Modi G, Antonio T, Reith M, Dutta A. Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule. Journal of Medicinal Chemistry. 57: 1557-72. PMID 24471976 DOI: 10.1021/Jm401883V |
0.795 |
|
| 2014 |
Sharma H, Santra S, Debnath J, Antonio T, Reith M, Dutta A. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model. Bioorganic & Medicinal Chemistry. 22: 311-24. PMID 24315194 DOI: 10.1016/J.Bmc.2013.11.017 |
0.394 |
|
| 2013 |
Santra S, Xu L, Shah M, Johnson M, Dutta A. D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model. Acs Chemical Neuroscience. 4: 1382-92. PMID 23906010 DOI: 10.1021/Cn400106N |
0.821 |
|
| 2013 |
Biswas S, Dutta A, Debnath M, Dolai M, Das KK, Ali M. A novel thermally stable hydroperoxo-copper(II) complex in a Cu(N2O2) chromophore of a potential N4O2 donor Schiff base ligand: synthesis, structure and catalytic studies. Dalton Transactions (Cambridge, England : 2003). 42: 13210-9. PMID 23884097 DOI: 10.1039/c3dt51359a |
0.466 |
|
| 2013 |
Gopishetty B, Zhang S, Kharkar PS, Antonio T, Reith M, Dutta AK. Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors. Bioorganic & Medicinal Chemistry. 21: 3164-74. PMID 23623679 DOI: 10.1016/J.Bmc.2013.03.059 |
0.465 |
|
| 2013 |
Johnson M, Antonio T, Reith ME, Dutta AK. Correction to Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization. Journal of Medicinal Chemistry. 56: 589-90. PMID 23289730 DOI: 10.1021/jm301634c |
0.473 |
|
| 2013 |
Kuzhikandathil EV, Cote S, Santra S, Dutta AK. Interaction of D₃ preferring agonist (-)-Nâ¶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-Nâ¶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human Dâ‚‚L, Dâ‚‚S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels. Naunyn-Schmiedeberg's Archives of Pharmacology. 386: 97-105. PMID 23160988 DOI: 10.1007/S00210-012-0811-6 |
0.475 |
|
| 2013 |
Shah M, Voshavar C, Xu L, Modi G, Dutta A. Evaluation of multifunctional dopamine agonists in modulation of alpha-synuclein induced aggregation and toxicity: implication in neuroprotective treatment of Parkinson's disease F1000research. 4. DOI: 10.7490/F1000Research.1094643.1 |
0.736 |
|
| 2012 |
Gogoi S, Biswas S, Modi G, Antonio T, Reith ME, Dutta AK. Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency. Acs Medicinal Chemistry Letters. 3: 991-996. PMID 23275802 DOI: 10.1021/Ml3002117 |
0.799 |
|
| 2012 |
Johnson M, Antonio T, Reith ME, Dutta AK. Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization. Journal of Medicinal Chemistry. 55: 5826-40. PMID 22642365 DOI: 10.1021/Jm300268S |
0.521 |
|
| 2011 |
Dutta AK, Gopishetty B, Gogoi S, Ali S, Zhen J, Reith M. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents. European Journal of Pharmacology. 671: 39-44. PMID 21963455 DOI: 10.1016/J.Ejphar.2011.09.162 |
0.364 |
|
| 2011 |
Gopishetty B, Hazeldine S, Santra S, Johnson M, Modi G, Ali S, Zhen J, Reith M, Dutta A. Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents. Journal of Medicinal Chemistry. 54: 2924-32. PMID 21446715 DOI: 10.1021/Jm200020A |
0.707 |
|
| 2011 |
Kortagere S, Cheng SY, Antonio T, Zhen J, Reith ME, Dutta AK. Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies. Biochemical Pharmacology. 81: 157-63. PMID 20833147 DOI: 10.1016/J.Bcp.2010.08.026 |
0.452 |
|
| 2010 |
Ghosh SK, Bandyopadhyay D, Ghosh A, Dutta A, Biswas S, Mandal RK, Jamadar NS. Mucocutaneous features of hand, foot, and mouth disease: a reappraisal from an outbreak in the city of Kolkata. Indian Journal of Dermatology, Venereology and Leprology. 76: 564-6. PMID 20827002 DOI: 10.4103/0378-6323.69042 |
0.462 |
|
| 2010 |
Li C, Biswas S, Li X, Dutta AK, Le W. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. Journal of Neuroscience Research. 88: 2513-23. PMID 20623619 DOI: 10.1002/Jnr.22405 |
0.715 |
|
| 2010 |
Ghosh B, Antonio T, Gopishetty B, Reith M, Dutta A. Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol. Bioorganic & Medicinal Chemistry. 18: 5661-74. PMID 20605099 DOI: 10.1016/J.Bmc.2010.06.025 |
0.689 |
|
| 2010 |
Ghosh B, Antonio T, Reith ME, Dutta AK. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease. Journal of Medicinal Chemistry. 53: 2114-25. PMID 20146482 DOI: 10.1021/Jm901618D |
0.694 |
|
| 2010 |
Zhen J, Antonio T, Dutta AK, Reith ME. Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. Journal of Neuroscience Methods. 188: 32-8. PMID 20122961 DOI: 10.1016/J.Jneumeth.2010.01.031 |
0.317 |
|
| 2010 |
Schmitt KC, Mamidyala S, Biswas S, Dutta AK, Reith ME. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter. Journal of Neurochemistry. 112: 1605-18. PMID 20067583 DOI: 10.1111/J.1471-4159.2010.06583.X |
0.54 |
|
| 2010 |
Ghosh B, Antonio T, Zhen J, Kharkar P, Reith ME, Dutta AK. Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models. Journal of Medicinal Chemistry. 53: 1023-37. PMID 20038106 DOI: 10.1021/Jm901184N |
0.689 |
|
| 2009 |
Kharkar PS, Batman AM, Zhen J, Beardsley PM, Reith ME, Dutta AK. Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters. Chemmedchem. 4: 1075-85. PMID 19449323 DOI: 10.1002/Cmdc.200900085 |
0.312 |
|
| 2009 |
Brown DA, Mishra M, Zhang S, Biswas S, Parrington I, Antonio T, Reith ME, Dutta AK. Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor. Bioorganic & Medicinal Chemistry. 17: 3923-33. PMID 19427222 DOI: 10.1016/J.Bmc.2009.04.031 |
0.683 |
|
| 2008 |
Brown DA, Kharkar PS, Parrington I, Reith ME, Dutta AK. Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model. Journal of Medicinal Chemistry. 51: 7806-19. PMID 19053758 DOI: 10.1021/Jm8008629 |
0.472 |
|
| 2008 |
Dutta AK, Ghosh B, Biswas S, Reith ME. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action. European Journal of Pharmacology. 589: 73-9. PMID 18561912 DOI: 10.1016/J.Ejphar.2008.05.008 |
0.688 |
|
| 2008 |
Biswas S, Hazeldine S, Ghosh B, Parrington I, Kuzhikandathil E, Reith ME, Dutta AK. Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. Journal of Medicinal Chemistry. 51: 3005-19. PMID 18410082 DOI: 10.1021/Jm701524H |
0.758 |
|
| 2008 |
Biswas S, Zhang S, Fernandez F, Ghosh B, Zhen J, Kuzhikandathil E, Reith ME, Dutta AK. Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. Journal of Medicinal Chemistry. 51: 101-17. PMID 18072730 DOI: 10.1021/Jm070860R |
0.752 |
|
| 2005 |
Biswas S, Bhattacharyya J, Dutta AG. Oxidant induced injury of erythrocyte-role of green tea leaf and ascorbic acid. Molecular and Cellular Biochemistry. 276: 205-10. PMID 16132702 DOI: 10.1007/s11010-005-4062-4 |
0.469 |
|
| 2004 |
Zhen J, Maiti S, Chen N, Dutta AK, Reith ME. Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and Aspartate 68 in the human dopamine transporter. European Journal of Pharmacology. 506: 17-26. PMID 15588620 DOI: 10.1016/J.Ejphar.2004.10.028 |
0.348 |
|
| 2004 |
Dutta AK, Venkataraman SK, Fei XS, Kolhatkar R, Zhang S, Reith ME. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. Bioorganic & Medicinal Chemistry. 12: 4361-73. PMID 15265488 DOI: 10.1016/J.Bmc.2004.06.019 |
0.456 |
|
| 2002 |
Dutta AK, Fei XS, Reith ME. A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors. Bioorganic & Medicinal Chemistry Letters. 12: 619-22. PMID 11844685 |
0.448 |
|
| 1996 |
Wiley JL, Compton DR, Gordon PM, Siegel C, Singer M, Dutta A, Lichtman AH, Balster RL, Razdan RK, Martin BR. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol. Neuropharmacology. 35: 1793-804. PMID 9076759 DOI: 10.1016/S0028-3908(96)00120-7 |
0.33 |
|
| 1980 |
Saha PC, Dutta AK, Ghosh BN. Sexual behaviour pattern of the male STD patients attending a treatment centre in Calcutta. Indian Journal of Public Health. 24: 16-22. PMID 6894135 |
0.392 |
|
| 1950 |
DUTTA AT, GHOSH BK, GUPTA JC. The seasonal variation of alkaloids in different parts of Holarrhena antidysenterica Wall. and the alkaloid content in the bark at different ages. Part 1. The Indian Journal of Medical Research. 38: 467-72. PMID 14840881 |
0.383 |
|
| Show low-probability matches. |